ACRS Aclaris Therapeutics Inc.

0.87
+0.07  (+9%)
Previous Close 0.8
Open 0.8
Price To Book 0.26
Market Cap 36,122,733
Shares 41,368,224
Volume 2,741,048
Short Ratio
Av. Daily Volume 1,206,265

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data did not meet primary endpoint - June 26, 2019.
ATI-502 (ATI-50002-AA-201) - dose ranging
Alopecia areata
Development to be discontinued - noted August 8, 2019.
ATI-502 (VITI-201 Topical)
Vitiligo
Phase 2 data met primary endpoint and some secondary endpoints - July 30, 2019. Partner required for further development.
ATI-501 (AUAT-201 Oral)
Alopecia areata
Approval announced December 15, 2017.
ESKATA (hydrogen peroxide)
Seborrheic keratosis (SK)
Phase 3 data due 2H 2019.
A-101 THWART-1 and THWART-2
Common warts (verruca vulgaris)
Phase 2 interim data released June 28, 2018.
ATI-502 AA-202 Topical - PK/safety
Alopecia areata
Phase 2 6-month data noted increase in hair count of 8.6 hairs/cm2. 12 month data due YE 2019.
ATI-502 (ATI-50002-AGA-201) - open label
Androgenetic alopecia (AGA) - Hair loss
Phase 2 trial completed.
ATI-502 (AD-201 Topical)
Atopic dermatitis (AD)
Phase 1/2 has commenced dosing - August 8, 2019.
ATI-450
Rheumatoid arthritis (RA)

Latest News

  1. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aclaris Therapeutics, Inc. - ACRS
  2. Zhang Investor Law Reminds Investors of Deadline in Securities Class Action Lawsuit Against Aclaris Therapeutics, Inc. – ACRS
  3. Aclaris Therapeutics halts marketing efforts for one of its skin disorder drugs
  4. LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Aclaris Therapeutics, Inc. To Contact The Firm
  5. SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
  6. Edited Transcript of ACRS earnings conference call or presentation 8-Aug-19 9:00pm GMT
  7. INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
  8. ROSEN, A LEADING LAW FIRM, Reminds Aclaris Therapeutics, Inc. Investors of Important September 30th Deadline in Securities Class Action – ACRS
  9. Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against 3M Company, Aclaris Therapeutics, and Curaleaf and Encourages Investors to Contact the Firm
  10. ROSEN, A TOP RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Aclaris Therapeutics, Inc.; Encourages Investors with Losses in Excess of $100K to Contact the Firm – ACRS
  11. Pacira (PCRX) Q2 Earnings and Revenues Surpass Estimates
  12. Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
  13. Aclaris Therapeutics Reports Second Quarter 2019 Financial Results, Provides Business Strategy Update and Provides Update on Clinical and Commercial Developments
  14. ACLARIS THERAPEUTICS, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District for the Southern District of New York against Aclaris Therapeutics, Inc.